Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Haas

Showing results (491-500 of 554) with videos related to

Pageof 56
Sort By:
Journal for Immunotherapy of Cancer|March 22, 2023
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2024
Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non-small cell lung cancer, and renal cell carcinomaJason J Luke, Georgina V Long, Caroline Robert, et al.
Kidney Cancer (Clifton, Va.)|October 19, 2018
Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC-A Possible Path ForwardL C Harshman, C G Drake, N B Haas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2022
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Cancer Research Communications|February 22, 2026
Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid TumorsJong Chul Park, David Berz, Manish R Sharma, et al.
BMC Medical Genomics|March 11, 2025
A genome-wide association study of methamphetamine use among people with HIVA Venkataraman, T Jia, S A Ruderman, et al.
JACC. Cardiooncology|July 10, 2024
Social Determinants of Health Mediate Racial Disparities in Cardiovascular Disease in Men With Prostate CancerBiniyam G Demissei, Kyunga Ko, Anran Huang, et al.
European Urology Oncology|November 5, 2023
Validation of Biomechanical Computed Tomography for Fracture Risk Classification in Metastatic Hormone-sensitive Prostate CancerJohn K Lin, Caleb M Hearn, Emily Getzen, et al.
The Lancet. Oncology|September 2, 2022
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialThomas Powles, Piotr Tomczak, Se Hoon Park, et al.
Science Translational Medicine|November 9, 2022
BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustionIn-Young Jung, Vivek Narayan, Sierra McDonald, et al.
Pageof 56

Showing results (491-500 of 554) with videos related to

Sort By:
Pageof 56
Journal for Immunotherapy of Cancer|March 22, 2023
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2024
Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non-small cell lung cancer, and renal cell carcinomaJason J Luke, Georgina V Long, Caroline Robert, et al.
Kidney Cancer (Clifton, Va.)|October 19, 2018
Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC-A Possible Path ForwardL C Harshman, C G Drake, N B Haas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2022
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Cancer Research Communications|February 22, 2026
Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid TumorsJong Chul Park, David Berz, Manish R Sharma, et al.
BMC Medical Genomics|March 11, 2025
A genome-wide association study of methamphetamine use among people with HIVA Venkataraman, T Jia, S A Ruderman, et al.
JACC. Cardiooncology|July 10, 2024
Social Determinants of Health Mediate Racial Disparities in Cardiovascular Disease in Men With Prostate CancerBiniyam G Demissei, Kyunga Ko, Anran Huang, et al.
European Urology Oncology|November 5, 2023
Validation of Biomechanical Computed Tomography for Fracture Risk Classification in Metastatic Hormone-sensitive Prostate CancerJohn K Lin, Caleb M Hearn, Emily Getzen, et al.
The Lancet. Oncology|September 2, 2022
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialThomas Powles, Piotr Tomczak, Se Hoon Park, et al.
Science Translational Medicine|November 9, 2022
BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustionIn-Young Jung, Vivek Narayan, Sierra McDonald, et al.
Pageof 56